Hikmat Abdul Razeq

Deputy Director General, Chief Medical Officer, Professor and Chairman, Department of Internal Medicine

Education and Training

M.B./B.S. University of Jordan, Jordan
1996-1997 Fellowship, Bone Marrow Transplantation Cleveland Clinic Foundation, USA
1993-1996 Fellowship, Hematology & Medical Oncology Cleveland Clinic Foundation, USA
1988-1990 Intern and Resident (Internal Medicine) Jordan University Hospital, Jordan
1992-1993 chief Resident, Internal Medicine New York Medical College, USA
1991-1992 Resident, Internal Medicine, New York Medical College, USA

Board Certifications

American Board of Medical Oncology
American Board of Hematology
American Board of Internal Medicine

Experience

2012-Present Chief Medical Officer & Deputy Director-General King Hussein Cancer Center (KHCC), Jordan
2010-Present Director, Breast Cancer ServiceKHCC, Jordan
2004-Present Chairman, Department of Internal Medicine Head, Section of Hematology & Medical Oncology Consultant, Hematologist and Medical Oncologist, KHCC, Jordan
1999-2004 Head, Hematology and Medical Oncology Consultant, Hematologist and Medical Oncologist Department of Internal Medicine, King Fahad Armed Forces Hospital, Kingdom of Saudi Arabia
1997-1999 Consultant; Internist, Hematologist and Medical Oncologist Detroit Mercy Hospital, USA
1996-1997 Special Senior Fellow, Bone Marrow Transplantation Unit, The Cleveland Clinic Foundation, USA

Professional Memberships

American College of Physicians
American Society of Hematology
American Society of Clinical Oncology
European Society of Medical Oncology
International Society of Thrombosis and Haemostasis

Publications

Book Title: Global Cancer Care (2015) Chapter: Cancer Care in Jordan USA
Book Title: Anticoagulants, Antiplatelets, and Thrombolytics (2004) Chapter: Anticoagulation Publisher: Humana Press, USA
Book Title: Deep Vein Thrombosis (2011) Chapter: Cancer and Thrombosis Publisher: InTech
Book Title: Prophylaxis: Types, Procedures and Clinical Implications (Ongoing) Chapter: DVT prophylaxis in medical patients Publisher: Nova Science Publishers, Inc. New York
Abdel-Razeq H. Prognostic Significance of Serum Vitamin D Levels in Egyptian Females with Breast Cancer, Asian Pac J Cancer Prev. 2019 Apr 28;20(4):983-983.
Abdel-Razeq H, Shamieh O, Abu-Nasser M, Nassar M, Samhouri Y, Abu-Qayas B, Asfour J, Jarrah J, Abdelrahman Z, Ameen Z, Al-Hawamdeh A, Alomari M, Al-Tabba' A, Al-Rimawi D, Hui D. Intensity of Cancer Care Near the End of Life at a Tertiary Care Cancer Center in Jordan. J Pain Symptom Manage. 2019 Jun;57(6):1106-1113
Qdaisat A, Al Soud R, Wu CC, Rojas Hernandez CM, Li J, Meng QH, Abdel-Razeq H, Yeung SJ.Poor performance of D-Dimer in excluding venous thromboembolism among patients with lymphoma and leukemia. Haematologica. 2019 Jan 10. pii: haematol.2018.211466
Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, Smit K, Büller HR, van Es N; CAT prediction collaborators; CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019 Jan 3. pii: haematol.2018.209114
Abdel-Razeq H, Barbar M, Abu-Hejleh T, Mansour A. Cancer Care for Adolescents and Young Adults (AYA) in Jordan. East Mediterr Health J. 2018 Sep 6;24(7):687-695. doi: 10.26719/2018.24.7.687
Abdel-Razeq HN. Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer.Hematol Oncol Stem Cell Ther. 2018 May 19. pii: S1658-3876(18)30055-4.
Abdel-Razeq H, Finianos A, Taher AT. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients. Expert Rev Hematol. 2018 Jun;11(6):487-494. doi: 10.1080/17474086.2018.1480363
Abdel-Razeq H, Saadeh SS, Abu-Nasser M, Abdulelah H, Marie L, Salam M, Ali BA, Ibrahim M, Rimawi D. Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients. Onco Targets Ther. 2018;11:2091-2096
Abdel-Razeq H, Mansour A, Abdulelah H, Al-Shwayat A, Makoseh M, Ibrahim M, Abunasser M, Rimawi D, Al-Rabaiah A, Alfar R, Abufara A, Ibrahim A, Bawaliz A, Ismael Y. Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! Thromb J. 2018;16:2. doi: 10.1186/s12959-018-0161-9.
Abdel-Razeq H, Al-Omari A, Zahran F, Arun B. Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer. 2018;18(1):152. doi: 10.1186/s12885-018-4079-1.
Abdel-Razeq H, Mansour A, Saadeh SS, Abu-Nasser M, Makoseh M, Salam M, Abufara A, Ismael Y, Ibrahim A, Khirfan G, Ibrahim M. The Application of Current Proposed Venous Thromboembolism Risk Assessment Model for Ambulatory Patients With Cancer. Clin Appl Thromb Hemost. 2018;24(3):429-433.
Abdel-Razeq H, Mansour A. Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better? J Thromb Thrombolysis. 2017;44(3):399-405
Abdel-Razeq H, Marei L, Saadeh S, Abdulelah H, Abu-Nasser M, Salam M, Daana W, Al-Haj Ali B, Taqash A. From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer. Breast Cancer Res Treat. 2017;165(3):771-77
Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, Larsen AK, Elalamy I; COMPASS–CAT Working Group. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017;22(10):1222-1231
Abdel-Razeq H.The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in long-distance travelers. Letter to editor. Saudi Med J. 2017;38(5):561-562.
Abdel-Razeq H. Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Cancer Manag Res. 2016;8:127-128.
Abdel-Razeq H, Mansour. Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients.
Drug Des Devel Therb. 2016;10: 2677-2679
van der Hulle T, den Exter PL, Planquette B, Meyer G, Soler S, Monreal M, Jiménez D, Portillo AK, O'Connell C, Liebman HA, Shteinberg M, Adir Y, Tiseo M, Bersanelli M, Abdel-Razeq HN, Mansour AH, Donnelly OG, Radhakrishna G, Ramasamy S, Bozas G, Maraveyas A, Shinagare AB, Hatabu H, Nishino M, Huisman MV, Klok FA.
Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost. 2016;14(1):105-13
Abdel-Razeq H, Attiga F, Mansour A. Cancer care in Jordan. Hematol Oncol Stem Cell Ther. 2015; 8(2):64-70.
Mansour A, Qandeel M,Abdel-Razeq H, Abu Ali HA. MR imaging features of intracranial primary CNS lymphoma in immune competent patients.
Cancer Imaging 2014, 14:22
Mansour A, Ismael Y, Abdel-Razeq H. (Corresponding Autho). Inferior vena cava filters in patients with advanced-stage cancer. Hematol Oncol Stem Cell Ther. 2014;7(4):136-41
Mansour A, Turfa R, Abu-Nasser M, Ismael Y, Abdel-Razeq H . (Corresponding Author). The application of clinical variables and models to predict pulmonary embolism in cancer patients. A comprehensive single cancer center experience
Patient Prefer Adherence. 2013;7:1111-6
Abdel-Razeq H, Abbasi S, Saadi I, Jaber R, Abdelelah H. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study. Drug Des Devel Ther. 2013;7:939-44
Abdel-Razeq H, Awidi A. Bone Health in Breast Cancer Survivors J Cancer Res Ther. 2011;7(3):256-63.
Abdel-Razeq H, Marei L.Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics. 2011;5:87-94
Abdel-Razeq H, Ismael Y Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism. A play-it-safe practical approach! Ther Clin Risk Manag. 2011;7:213-7
Abdel-Razeq H , Mansour A , Ismael Y, Abdulelah H Inferior Vena Cava filters in cancer patients. To filter or not to filter! Ther Clin Risk Manag. 2011:7 99–102
Abdel-Razeq H , Mansour A , Ismael Y. Incidental Pulmonary Embolism in Cancer Patients: Clinical Characteristics and Outcome; A Comprehensive Cancer Center Experience. Vasc Health Risk Manag. 2011:7 153–158
Abdel-Razeq H.Caring for the Breast Cancer Survivor. Am J Med. 2011;124(2):e11
Abdel-Razeq H, Albadainah F , Hijjawi S, Mansour A,Treish I Venous Thromboembolism (VTE) in Hospitalized Cancer Patients: Prophylaxis Failure or Failure to Prophylax. J Thromb Thrombolysis. 2011; 3: 107-112
Abdel-Razeq H Venous Thromboembolism Prophylaxis for Hospitalized Medical Patients, Current Status and Strategies to Improve!
Ann Thorac Med. 2010; 5:195-200
Abdel-Razeq H, Hijjawi S, Abdulelah H, Amarin R, Asawaeer M, Shaheen H.The impact of recently published negative erythropoiesis-stimulating agent studies on the clinical management of cancer-related anemia at a single center. Hematol Oncol Stem Cell Ther. 2010;3(2):78-83
Abdel-Razeq HN, Hijjawi SB, Jallad SG, Ababneh BA. Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience.
J Thromb Thrombolysis. 2010;30(3):286-93
Abdel-Razeq H.Pentasaccharides: a New Class of Anticoagulants in Clinical Practice
Journal of Coagulation Disorders 2010; 2: 53-59
A Hilali, H. Abdel-Razeq A Novel Syndrome Complicating Sickle Cell Disease: Generalized Bone Marrow Necrosis Qatar Medical Journal 2007; 16(2):54-58
Abdel-Razeq HN, Zaru L, Omoti C.The pattern of fetal hemoglobin changes in patients with malignancy on chemotherapy.Saudi Med J. 2007;28(4):658.
Al-Hilali A, Wulff K, Abdel-Razeq H, Saud KA, Al-Gaili F, Herrmann FH. Analysis of the novel factor X gene mutation Glu51Lys in two families with factor X- Riyadh anomaly. Thromb Haemost. 2007;97(4):542-5
Abdel-Razeq H, Mousa S Thalidomide, A new old drug in the treatment of Multiple Myeloma Drugs Fut. 2004; 29(10):1059-1063
Mousa SA, Abdel-Razeq HN Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge? Cardiovasc Drug Rev. 2005;23(4):331-44
Abdel-Razeq H, Bajouda A, Khalil M, Chamsi-Pasha H Warfarin resistance in a patient with mechanical valve prosthesis Saudi Med J 2005; 26 ( 2 ) 332-333
Abdel-Razeq H, Radwi G Duration of anticoagualtion after first episode of unprovoked venous thromboembolism Saudi Med J 2004; 25 ( 11 ) 1776 -1777
Abdel-Razeq, HN Pentasaccharides, the new anticoagulants Saudi Med J 2004; 25 (8): 893-899
Abdel-Razeq H, Bajouda A, Khalil M, Ashmeg A
Treating Heparin-Induced Thrombocytopenia: The unconventional way ! Saudi Med J. 2004;25(9):1258-1260
Abdel-Razeq HN Cancer-related anemia
Saudi Med J. 2004; 25 (1): 15-20
Abdel-Razeq H, Qari M, Kristensen J, Alizeidah H, Al-Sayegh F, Marashi M, Alzeer A, Al-Amoudi O, Qutub H, Al-Humiadi AA, Husted S. Mousa SA; GCC Thrombosis Study Group. Guidelines for diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Methods Mol Med. 2004; 93:267-92.
Qari M, Abdel-Razeq H, Alzer A, Alizadeh H, Kristensen J, Al-Sayegh F, Qutub H, Marashi M, Husted S, Mousa S. Recent advances in the diagnosis and treatment of deep vein thrombosis: a regional consensus. Curr Opin Investig Drugs. 2003; 4 (3): 309-15.
Abdel-Razeq, H Recent advances in venous thromboembolic prophylaxis in major orthopedic surgery. A regional perspective. Annals of Saudi Medicine 2003; 23:39-42
Abdel-Razeq H, Pohlman B, Andresen S, Kalaycio, M, Overmoyer B, Wise K, Dannley R, DeMars D, Goormastic M, Bolwell B.A randomized study of multi-day infusion of autologo peripheral blood progenitor cells.
Bone Marrow Transplant, 1998; 21 (3):221-3
Tbakhi A, Pettay J, Sreenan JJ, Abdel-Razeq H, Kalaycio M, Hoeltge GM, Miller ML,Tubbs RR.
Comparative analysis of interphase FISH and RT-PC detect bcr-abl tranlocation in chronic myelogenous leukemia and related disorders. Am J Clin Pathol. 1998 Jan; 109 (1): 16-23
Abdel-Razeq H, Bolwell BJ A 68-year old woman with high serum protein and no symptomsClevlnd.leve Clin J Med. 1997; 64(8): 03-6

Academic Classification

Full Member

Contact Information

Email Address: habdelrazeq@khcc.jo
Phone Number: 0096265300460 - 1000